• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bridge Medicines appoints William J. Polvino chief executive officer

Bridge Medicines appoints William J. Polvino chief executive officer

March 28, 2017
CenterWatch Staff

Bridge Medicines, a drug discovery company focused on advancing promising early technologies from concept to clinic, announced the appointment of William J. Polvino, M.D., as chief executive officer (CEO). In conjunction, Kathleen Metters, Ph.D., who served as the interim CEO upon the establishment of Bridge Medicines in October 2016, will continue to have an operating role within Bridge Medicines, and will Chair the Scientific Advisory Board.

Bridge Medicines, launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceutical, in partnership with Deerfield Management and Bay City Capital, is an initiative that extends the work of the independent, nonprofit Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). Tri-I TDI, also a collaborative venture of the three research institutions and Takeda, is working on approximately 50 early-stage drug discovery projects spanning therapeutic areas that include infectious disease, oncology, neuropsychiatry and rare diseases. As CEO of Bridge Medicines, Dr. Polvino will be responsible for building a portfolio of early-stage drug discovery projects and advancing each program from animal proof of principle to clinical trials by providing expert clinical, operational and managerial expertise.

Carl S. Goldfischer, managing director of Bay City Capital and executive chairman of Bridge Medicines, remarked, "As an entrepreneur and executive of exceptional skill, Bill is ideally equipped to lead Bridge Medicines as the company embarks on its mission. We look forward to benefiting from Bill's expertise as Bridge Medicines seeks to harness the combined strengths of academic discovery and industrial know-how to change the paradigm of drug development and help to transform New York into one of the world's leading biotechnology hubs."

Dr. Polvino commented, "Bridge Medicines is in an honored position to work with some of the world's most renowned scientists and institutions. It is a privilege to take their groundbreaking work forward for the benefit of patients. As CEO, I will work closely with our esteemed partners to ensure the company succeeds in its mission of accelerating the transition of promising projects into the clinic."

Dr. Polvino is a pharmaceutical entrepreneur with more than 26 years of experience in the pharmaceutical and healthcare arena. Most recently, Dr. Polvino was president and chief executive officer of Veloxis Pharmaceuticals, a public biotechnology company that deploys proprietary formulation technology to develop and commercialize innovative oral drug products. Prior to Veloxis, Dr. Polvino held positions at Helsinn Therapeutics (formerly Sapphire Therapeutics), where he also served as the company's president and CEO. During his tenure at Helsinn, he advanced novel in-licensed, preclinical stage, new chemical entities into late-stage clinical development and registration in the supportive oncology space. Dr. Polvino has also held executive and senior-level positions in drug development at Merck, Wyeth and Theravance.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing